AtaiBeckley Inc ATAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
-
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
-
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
-
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
-
Are ATAI, FHB, PATK Obtaining Fair Deals for their Shareholders?
-
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI)
-
Shareholder Alert: Ademi LLP investigates whether AtaiBeckley Inc. is obtaining a Fair Price for Public Shareholders
-
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether AtaiBeckley Inc. is Obtaining a Fair Price for its Shareholders
Trading Information
- Previous Close Price
- $7.18
- Day Range
- $7.23–7.25
- 52-Week Range
- $3.27–7.25
- Bid/Ask
- $7.24 / $7.25
- Shares Outstanding
- 369.95M
- Market Cap
- $2.68B
- Volume/Avg
- 9,233 / 11M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 564.99
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 99
- Website
- https://www.ataibeckley.com
Valuation
|
Metric
|
ATAI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 13.34 |
Price/Sales | 564.99 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATAI
|
|---|---|
Quick Ratio | 9.83 |
Current Ratio | 10.02 |
Interest Coverage | −2,535.99 |
Quick Ratio
ATAI
Profitability
|
Metric
|
ATAI
|
|---|---|
Return on Assets (Normalized) | −94.49% |
Return on Equity (Normalized) | −127.53% |
Return on Invested Capital (Normalized) | −121.95% |
Return on Assets
ATAI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|YjG^%H | LOCK|^&kK$ | $126B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#$^&<xf | LOCK|M!lgx | $81B | |||
| argenx SE ADR
ARGX
| LOCK|dy%<Z> | LOCK|@fj | $55B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>%BgP?@ | LOCK|%KPh | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?R@CTn | LOCK|&% | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|B%>Hk? | LOCK|%^ny# | $29B | |||
| Incyte Corp
INCY
| LOCK|@#v@CQV | LOCK|>< | $24B | |||
| Moderna Inc
MRNA
| LOCK|vFc$d?> | LOCK|Vd | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|VG^W@F | LOCK|S& | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|crq&<f | LOCK|Xv | $17B |
United States